Info

🌱 來自: Stage II-of-Preoperative Chemotherapy for Operable Breast Cancer

T-DM1

• Ado-trastuzumab emtansine (Kadcyla)
• Mechanism: HER2-targeted antibody–drug conjugated to the antimicrotubular maytansinoid agent, mertansine (DM1)
• Dosing: 3.6 mg/kg every 3 wks, no renal or hepatic adjustments
• PK/PD: T1/2 ∼4 d
• AEs: Hepatotoxicity, ↓ LVEF, pancytopenia, GI tox, neuropathy, ↓ K
• DDI: CYP3A4 substrate